HES1 and central nervous system cancer: In two CGGA mRNA datasets, we found that glioma patients with high expressions of METTL3, IGF2BP2, VEGFA, TIMP1, HES1, COL18A1, TK1, DNAJB11, CENPK, NASP, and U2AF2 have a shorter overall survival (HR > 1, p < 0.05) (Figure 5A and Supplementary Table S8), while those with high expressions of PHLPP2, ATP6V1A, and DLL3 show a good overall survival (HR < 1, p < 0.05) (Figure 5B and Supplementary Table S8).